Back | Next |
home / stock / ions / ions message board
Subject | By | Source | When |
---|---|---|---|
Headed to 57 I feel it in my bones! | Ocotillio | investorshub | 11/07/2018 8:27:03 PM |
Ready to Rocket! | Ocotillio | investorshub | 10/31/2018 3:24:02 PM |
Jimmy: The FDA is seriously underfunded and being pulled | shub | investorshub | 09/19/2018 6:10:02 PM |
The advisory committee recommended approval. A very small | jimmy667 | investorshub | 08/28/2018 1:54:56 AM |
drbio45 | investorshub | 06/17/2018 2:41:08 PM | |
So our new drug that gives a | shub | investorshub | 10/24/2017 7:05:30 PM |
Ionis Pharmaceuticals, Inc. (NASDAQ:$IONS): Stochastic Analysis | HERMES8 | investorshub | 10/13/2017 7:32:42 PM |
So, let's see.... | shub | investorshub | 10/13/2017 6:09:55 PM |
Thanks Capecod. | shub | investorshub | 09/19/2017 6:58:14 PM |
If you want to be on a large | Capecod1 | investorshub | 09/19/2017 1:00:16 AM |
That would explain the paucity of postings. | shub | investorshub | 09/18/2017 5:55:34 PM |
Is there a private board on this platform | Capecod1 | investorshub | 09/16/2017 5:57:36 PM |
And between us we darn near own this board..grin. | shub | investorshub | 08/08/2017 7:37:37 PM |
I like this company too. | Thoro | investorshub | 08/08/2017 6:36:36 PM |
Thanks for the updates Thoro; | shub | investorshub | 08/08/2017 6:16:08 PM |
IONS, $AKCA, Akcea and Ionis Announce Submission of | Thoro | investorshub | 07/27/2017 2:39:29 PM |
Anyone think this will be over $70 by | Thoro | investorshub | 07/25/2017 9:02:26 PM |
Ionis Pharmaceuticals reports phase 1/2 clinical study results | Thoro | investorshub | 07/17/2017 5:14:06 PM |
Ionis Pharmaceuticals presents new data at peripheral nerve | Thoro | investorshub | 07/17/2017 5:11:10 PM |
Ionis receives $10 mln milestone payment from Biogen | Thoro | investorshub | 07/17/2017 5:09:35 PM |
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
Ionis announces positive detailed results from the HALOS Study of ION582 in people with Angelman syndrome PR Newswire ION582 showed robust and consistent benefit in communication, cognition and motor function in a broad patient population evaluated with a comprehensive set o...
Ionis to hold second quarter 2024 financial results webcast PR Newswire Webcast scheduled for Thursday, August 1 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 19, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced ...
Ionis completes enrollment in pivotal trial evaluating zilganersen in people living with Alexander disease PR Newswire Zilganersen is the first investigational medicine in clinical development for people with Alexander disease, a rare, life-threatening neurological condition...